A Study of Chiglitazar in Patients With Metabolic Dysfunction-associated Steatohepatitis and Type 2 Diabetes Mellitus

A phase 2 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 300 participants.

Also called NCT07303803

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; quadruple masking; primary purpose treatment
Phase
Phase 2
Enrolled
  • 300 participants (planned count) (from the registry)
Sponsor
Registry
  • NCT NCT07303803
Started
(actual) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
China (from the registry)
Registry status
  • Recruiting (from the registry)

Technical summary

Registry record NCT07303803. Randomized; quadruple masking; primary purpose treatment. Start 2026-01-01 (actual); primary completion 2030-12-01 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
A Study of Chiglitazar in Patients With Metabolic Dysfunction-associated Steatohepatitis and Type 2 Diabetes Mellitus
Acronym
CHIG-MASH
Condition
MASH - Metabolic Dysfunction-Associated Steatohepatitis
Condition
T2DM (Type 2 Diabetes Mellitus)
Intervention (Drug)
Chiglitazar Placebo
Intervention (Drug)
Chiglitazar
Intervention (Drug)
vitamin E
Intervention (Drug)
Polyene Phosphatidyl choline
Lead sponsor
Shanghai Jiao Tong University School of Medicine (class: other)
Collaborator
Chipscreen Biosciences, Ltd. (class: industry)

Record details

Record id
cardio:ct-nct07303803
Content hash
a1c8234d10c8d22524688a4da53ae497d21f7e3f562923006efba2e41a6d2f0f